PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 8906810-11 1996 These results document a novel pathway in human lymphocytes leading from CD38 ligation to CD73 expression, which may result in the rapid acquisition of new functions, including increased purine salvage, increased sensitivity to Ag-induced activation, and the generation of adenosine (Ado) for Ado receptor signaling. Adenosine 273-282 CD38 molecule Homo sapiens 73-77 8906810-11 1996 These results document a novel pathway in human lymphocytes leading from CD38 ligation to CD73 expression, which may result in the rapid acquisition of new functions, including increased purine salvage, increased sensitivity to Ag-induced activation, and the generation of adenosine (Ado) for Ado receptor signaling. Adenosine 284-287 CD38 molecule Homo sapiens 73-77 8759717-4 1996 Two other nucleotide-hydrolyzing activities were induced on the T cell surface concomitantly with CD38: the human PC-1 molecule, a nucleotide phosphodiesterase/pyrophosphatase that produces AMP from NAD or ADP-ribose, and a nucleotidase that produces adenosine from AMP, but which may be distinct from the CD73 5"-nucleotidase. Adenosine 251-260 CD38 molecule Homo sapiens 98-102 34885748-1 2021 Although a monoclonal antibody targeting the multifunctional ectoenzyme CD38 is an FDA-approved drug, few small molecule inhibitors exist for this enzyme that catalyzes inter alia the formation and metabolism of the N1-ribosylated, Ca2+-mobilizing, second messenger cyclic adenosine 5"-diphosphoribose (cADPR). Adenosine 273-282 CD38 molecule Homo sapiens 72-76 34199285-3 2021 In the bone marrow niche, a chain of ectoenzymes, including CD38, produce immunosuppressive adenosine, inhibiting T cell proliferation as well as immunosuppressive cells. Adenosine 92-101 CD38 molecule Homo sapiens 60-64 35572492-10 2022 CD38 may play a role in MM and lung cancer by changing the bone marrow microenvironment through adenosine. Adenosine 96-105 CD38 molecule Homo sapiens 0-4 35091759-10 2022 Yet, the ectoenzymes of the canonical and non-canonical adenosinergic pathway (ENTPD1 and CD38) are upregulated, suggesting that adenosine is produced by both active adenosinergic pathways. Adenosine 129-138 CD38 molecule Homo sapiens 90-94 35196024-8 2022 RNA sequencing analyses highlighted modifications in the tolerant patients" transcriptomic profiles, particularly with overexpression of the ectoenzyme NT5E (encoding CD73), which could counterbalance CD38 enzymatic functions by producing adenosine. Adenosine 239-248 CD38 molecule Homo sapiens 201-205 35196024-11 2022 Thus, balance between a CD38-activated immune state and CD73-related production of adenosine may be a key regulator of operational tolerance. Adenosine 83-92 CD38 molecule Homo sapiens 24-28 33678520-1 2021 BACKGROUND: CD38, a druggable ectoenzyme, is involved in the generation of adenosine, which is implicated in tumour immune evasion. Adenosine 75-84 CD38 molecule Homo sapiens 12-16 33936090-4 2021 Surface CD38 expression is increased in different hematological and solid tumors, where it cooperates with other ecto-enzymes to produce the immunosuppressive molecule adenosine (ADO). Adenosine 168-177 CD38 molecule Homo sapiens 8-12 33936090-4 2021 Surface CD38 expression is increased in different hematological and solid tumors, where it cooperates with other ecto-enzymes to produce the immunosuppressive molecule adenosine (ADO). Adenosine 179-182 CD38 molecule Homo sapiens 8-12 33936090-6 2021 We therefore discuss these novel findings, examining the possible contribution of NAD+ depletion, along with ADO production, in the immunosuppressive activities of CD38 in the context of human tumors. Adenosine 109-112 CD38 molecule Homo sapiens 164-168 33418913-4 2021 Recent data suggest that, among the potential mechanisms behind the lack of responsiveness or resistance to anti-PD-L1/PD-1 antibodies, the CD38 metabolic pathways involving the immune-suppressive factor, adenosine, could play an important role. Adenosine 205-214 CD38 molecule Homo sapiens 140-144 31847204-3 2019 As an ectoenzyme, CD38 functions as a metabolic sensor catalyzing the extracellular conversion of NAD+ to the immunosuppressive factor adenosine (ADO). Adenosine 135-144 CD38 molecule Homo sapiens 18-22 31847204-3 2019 As an ectoenzyme, CD38 functions as a metabolic sensor catalyzing the extracellular conversion of NAD+ to the immunosuppressive factor adenosine (ADO). Adenosine 146-149 CD38 molecule Homo sapiens 18-22 31847204-4 2019 Other ectoenzymes, CD73 and CD203a, together with CD38, are also involved in the alternative axis of extracellular production of ADO, bypassing the canonical pathway mediated by CD39. Adenosine 129-132 CD38 molecule Homo sapiens 50-54 31552039-1 2019 Background: CD38 is involved in the adenosine pathway, which represents one of the immunosuppressive mechanisms in cancer. Adenosine 36-45 CD38 molecule Homo sapiens 12-16 31068926-14 2019 Along with the ability to deplete CD38+ malignant plasma cell populations which has led to their widespread therapeutic use, anti-CD38 antibodies are involved in the polarization and release of microvesicles characterized by the expression of multiple adenosine-producing molecules. Adenosine 252-261 CD38 molecule Homo sapiens 130-134 31069133-3 2019 Our working hypothesis is that adenosine (ADO), an immunosuppressive molecule along with the ectoenzymatic pathways (CD39-CD73 and CD38-CD203a/PC-1-CD73) controlling its production, are involved in the dynamics of NB cells in the BM. Adenosine 31-40 CD38 molecule Homo sapiens 131-135 31069133-3 2019 Our working hypothesis is that adenosine (ADO), an immunosuppressive molecule along with the ectoenzymatic pathways (CD39-CD73 and CD38-CD203a/PC-1-CD73) controlling its production, are involved in the dynamics of NB cells in the BM. Adenosine 42-45 CD38 molecule Homo sapiens 131-135 30587530-4 2019 The results obtained indicate that hAEC constitutively express a unique combination of functional ectoenzymes, driving the production of adenosine (ADO) via canonical (CD39, CD73) and alternative (CD38, CD203a/PC-1, CD73) pathways. Adenosine 137-146 CD38 molecule Homo sapiens 197-201 30587530-4 2019 The results obtained indicate that hAEC constitutively express a unique combination of functional ectoenzymes, driving the production of adenosine (ADO) via canonical (CD39, CD73) and alternative (CD38, CD203a/PC-1, CD73) pathways. Adenosine 148-151 CD38 molecule Homo sapiens 197-201 30826127-7 2019 CD38-targeting antibodies probably also reduce adenosine production in the bone marrow microenvironment, which may contribute to improved T cell activity. Adenosine 47-56 CD38 molecule Homo sapiens 0-4 30513816-4 2018 The production of extracellular adenosine is mediated by the cell surface ectoenzymes CD73, CD39, and CD38 and therapeutic agents have been developed to target these as well as the downstream adenosine receptors (A1R, A2AR, A2BR, A3R) to enhance anti-tumor immune responses. Adenosine 32-41 CD38 molecule Homo sapiens 102-106 30012853-3 2018 In vitro and in vivo studies demonstrate that CD38 inhibits CD8+ T-cell function via adenosine receptor signaling and that CD38 or adenosine receptor blockade are effective strategies to overcome the resistance. Adenosine 85-94 CD38 molecule Homo sapiens 46-50 30181171-1 2018 Overexpression of CD38 after PD-1/PD-L1 blockade increases extracellular adenosine levels and may contribute to acquired resistance to anti-PD-1/PD-L1 therapy. Adenosine 73-82 CD38 molecule Homo sapiens 18-22 29702148-7 2018 CD38-targeting antibodies probably also reduce adenosine production in the bone marrow microenvironment, which may contribute to improved T cell activity. Adenosine 47-56 CD38 molecule Homo sapiens 0-4 30221054-2 2018 Adenosine (ADO), an immunosuppressive molecule, is produced within MM patients" BM by adenosinergic ectoenzymes, starting from ATP (CD39/CD73) or NAD+ [CD38/CD203a(PC-1)/CD73]. Adenosine 0-9 CD38 molecule Homo sapiens 152-156 30221054-2 2018 Adenosine (ADO), an immunosuppressive molecule, is produced within MM patients" BM by adenosinergic ectoenzymes, starting from ATP (CD39/CD73) or NAD+ [CD38/CD203a(PC-1)/CD73]. Adenosine 11-14 CD38 molecule Homo sapiens 152-156 29731713-2 2018 Numerous studies have explored the role of CD38, CD39, CD203a/PC-1, and CD73 in generating extracellular adenosine (ADO) and thus in shaping the tumor niche in favor of proliferation. Adenosine 105-114 CD38 molecule Homo sapiens 43-47 29731713-3 2018 The findings shown here reveal that CIK cells are able to produce extracellular ADO via traditional (CD39/CD73) and/or alternative (CD38/CD203a/CD73 or CD203a/CD73) pathways. Adenosine 80-83 CD38 molecule Homo sapiens 132-136 29636685-5 2018 NAD+ is converted by CD38, CD203 and other ecto-enzymes to the Ca2+ mobilizing messengers cyclic ADP-ribose and ADP-ribose, and to adenosine. Adenosine 131-140 CD38 molecule Homo sapiens 21-25 29769837-3 2018 Alternatively, ADO can be generated starting from NAD+, which is metabolized by the concerted action of CD38, CD203a/PC-1, and CD73. Adenosine 15-18 CD38 molecule Homo sapiens 104-108 28373875-2 2017 One set of ectoenzymes-CD39, CD38, CD203a, and CD73-leads to the generation of adenosine (ADO) by metabolizing ATP and NAD+. Adenosine 79-88 CD38 molecule Homo sapiens 29-33 28373875-2 2017 One set of ectoenzymes-CD39, CD38, CD203a, and CD73-leads to the generation of adenosine (ADO) by metabolizing ATP and NAD+. Adenosine 90-93 CD38 molecule Homo sapiens 29-33 27761584-0 2016 Adenosine Generated in the Bone Marrow Niche Through a CD38-Mediated Pathway Correlates with Progression of Human Myeloma. Adenosine 0-9 CD38 molecule Homo sapiens 55-59 27761584-7 2016 Adenosine levels were significantly higher in the bone marrow plasma of patients with symptomatic myeloma and correlated with ISS staging, suggesting that adenosine is produced in the myeloma niche at micromolar levels by an ectoenzymatic network centered on CD38. Adenosine 0-9 CD38 molecule Homo sapiens 259-263 27761584-7 2016 Adenosine levels were significantly higher in the bone marrow plasma of patients with symptomatic myeloma and correlated with ISS staging, suggesting that adenosine is produced in the myeloma niche at micromolar levels by an ectoenzymatic network centered on CD38. Adenosine 155-164 CD38 molecule Homo sapiens 259-263 26091716-0 2015 CD56brightCD16- NK Cells Produce Adenosine through a CD38-Mediated Pathway and Act as Regulatory Cells Inhibiting Autologous CD4+ T Cell Proliferation. Adenosine 33-42 CD38 molecule Homo sapiens 53-57 24389178-6 2014 A recent observation is that CD38 may run an escape circuit leading to the production of adenosine. Adenosine 89-98 CD38 molecule Homo sapiens 29-33 23615966-8 2013 Also analyzed is the behavior of CD38 as an enzyme: CD38 is a component of a pathway leading to the production of adenosine in the tumor microenvironment, thus inducing local anergy. Adenosine 114-123 CD38 molecule Homo sapiens 33-37 23615966-8 2013 Also analyzed is the behavior of CD38 as an enzyme: CD38 is a component of a pathway leading to the production of adenosine in the tumor microenvironment, thus inducing local anergy. Adenosine 114-123 CD38 molecule Homo sapiens 52-56 23830401-7 2013 The study included the evaluation of the expression of TNF-alpha (a pro-inflammatory cytokine) and of an alternative pathway of adenosine generation run by CD38 (ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase) and PC-1 (ectonucleotide pyrophosphatase/phosphodiesterase 1, ENPP1). Adenosine 128-137 CD38 molecule Homo sapiens 156-160